Intensified treatment with high dose Rifampicin and Levofloxacin compared to standard treatment for adult patients with Tuberculous Meningitis (TBM-IT): Protocol for a randomized controlled trial

Trials

Volumn 12, Issue , 2011, Pages

  Heemskerk, Dorothee ^a   Day, Jeremy ^a   Chau, Tran T H ^a,b   Dung, Nguyen H ^c   Yen, Nguyen T B ^c   Bang, Nguyen D ^a,c   Merson, Laura ^a   Olliaro, Piero ^a,d   Pouplin, Thomas ^a   Caws, Maxine ^a   Wolbers, Marcel ^a   Farrar, Jeremy ^a  

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c Pham Ngoc Thach Hospital   (Viet Nam)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DEXAMETHASONE; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; PLACEBO; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; OFLOXACIN; TUBERCULOSTATIC AGENT;

ADD ON THERAPY; ADOLESCENT; ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HAZARD RATIO; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MORTALITY; NEUROIMAGING; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; THORAX RADIOGRAPHY; TOXOPLASMOSIS; TUBERCULOUS MENINGITIS; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DRUG COMBINATION; METHODOLOGY; NEUROLOGIC EXAMINATION; SAMPLE SIZE; TIME; TREATMENT OUTCOME; VIET NAM;

ADULT; ANTITUBERCULAR AGENTS; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; NEUROLOGIC EXAMINATION; OFLOXACIN; RESEARCH DESIGN; RIFAMPIN; SAMPLE SIZE; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MENINGEAL; VIETNAM;

EID: 79251623125     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-25     Document Type: Article

References (41)

1. Rich CB, Samuels AJ. Tuberculous meningitis treated with streptomycin. Can Med Assoc J 1948, 58(3):282-4. 1590837, 18906655.
2. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, Nguyen QH, Nguyen TT, Nguyen NH, Nguyen TN, Nguyen NL, Nguyen HD, Vu NT, Cao HH, Tran TH, Pham PM, Nguyen TD, Stepniewska K, White NJ, Tran TH, Farrar JJ. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004, 351(17):1741-51. 10.1056/NEJMoa040573, 15496623.
3. Torok ME, Chau TT, Mai PP, Phong ND, Dung NT, Chuong LV, Lee SJ, Caws M, de Jong MD, Hien TT, Farrar JJ. Clinical and microbiological features of HIV-associated tuberculous meningitis in Vietnamese adults. PLoS ONE 2008, 3(3):e1772. 10.1371/journal.pone.0001772, 2262136, 18350135.
4. Garg RK. Tuberculosis of the central nervous system. Postgrad Med J 1999, 75(881):133-40. 1741157, 10448488.
5. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR, . ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006, 174(8):935-52. 10.1164/rccm.200510-1666ST, 17021358, ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee.
6. Graham SM, Bell DJ, Nyirongo S, Hartkoorn R, Ward SA, Molyneux EM. Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection. Antimicrob Agents Chemother 2006, 50(2):407-13. 10.1128/AAC.50.2.407-413.2006, 1366879, 16436690.
7. Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother 1997, 41(12):2670-9. 164187, 9420037.
8. Wilkins JJ, Langdon G, McIlleron H, Pillai GC, Smith PJ, Simonsson US. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur J Clin Pharmacol 2006, 62(9):727-35. 10.1007/s00228-006-0141-z, 16685561.
9. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006, 50(4):1170-7. 10.1128/AAC.50.4.1170-1177.2006, 1426981, 16569826.
10. Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold AL, Lockman S, Oyewo A, Talbot EA, Kenyon TA, Moeti TL, Moffat HJ, Peloquin CA. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis 2005, 41(4):461-9. 10.1086/431984, 16028152.
11. Sahai J, Gallicano K, Swick L, Tailor S, Garber G, Seguin I, Oliveras L, Walker S, Rachlis A, Cameron DW. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997, 127(4):289-93.
12. Thwaites GE, Lan NT, Dung NH, Quy HT, Oanh DT, Thoa NT, Hien NQ, Thuc NT, Hai NN, Bang ND, Lan NN, Duc NH, Tuan VN, Hiep CH, Chau TT, Mai PP, Dung NT, Stepniewska K, White NJ, Hien TT, Farrar JJ. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J Infect Dis 2005, 192(1):79-88. 10.1086/430616, 15942897.
13. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharat S, Shandil RK, Kantharaj E, Balasubramanian V. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003, 47(7):2118-24. 10.1128/AAC.47.7.2118-2124.2003, 161844, 12821456.
14. Ostrow JH. Levels of rifampin in cerebrospinal fluid. Chest 1973, 63(4):648-9. 10.1378/chest.63.4.648, 4695373.
15. Strates M. Metabolism and Pharmacokinetics of the Antibiotic Rifampin. Drug Metabolism Reviews 1981, 12(1):159-218. 10.3109/03602538109011084, 7028436.
16. Ruslami R, Nijland H, Aarnoutse R, Alisjahbana B, Soeroto AY, Ewalds S, van Crevel R. Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis. Antimicrob Agents Chemother 2006, 50(2):822-3. 10.1128/AAC.50.2.822-823.2006, 1366934, 16436757.
17. Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother 2007, 51(7):2546-51. 10.1128/AAC.01550-06, 1913243, 17452486.
18. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, Palaci M, Dietze R. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006, 10(6):605-12.
19. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, Coleman DJ, Fourie B, Mitchison DA, . Gatifloxacin for TB (OFLOTUB) study team A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008, 12(2):128-38. Gatifloxacin for TB (OFLOTUB) study team.
20. Thwaites GE, Tran TH. Tuberculous meningitis: many questions, too few answers. Lancet Neurol 2005, 4(3):160-70.
21. el-Sadr WM, Perlman DC, Matts JP, Nelson ET, Cohn DL, Salomon N, Olibrice M, Medard F, Chirgwin KD, Mildvan D, Jones BE, Telzak EE, Klein O, Heifets L, Hafner R. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1998, 26(5):1148-58. 10.1086/520275, 9597244.
22. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007, 67(14):2077-99. 10.2165/00003495-200767140-00007, 17883288.
23. Ziganshina LE, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev 2008, (1):CD004795.
24. Thwaites GE, Duc Bang N, Huy Dung N, Thi Quy H, Thi Tuong Oanh D, Thi Cam Thoa N, Quang Hien N, Tri Thuc N, Ngoc Hai N, Thi Ngoc Lan N, Ngoc Lan N, Hong Duc N, Ngoc Tuan V, Huu Hiep C, Thi Hong Chau T, Phuong Mai P, Thi Dung N, Stepniewska K, Simmons CP, White NJ, Tinh Hien T, Farrar JJ. The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with Tuberculous meningitis. J Infect Dis 2005, 192(12):2134-41. 10.1086/498220, 16288379.
25. Akcali S, Surucuoglu S, Cicek C, Ozbakkaloglu B. In vitro activity of ciprofloxacin, ofloxacin and levofloxacin against Mycobacterium tuberculosis. Ann Saudi Med 2005, 25(5):409-12.
26. Paramasivan CN, Sulochana S, Kubendiran G, Venkatesan P, Mitchison DA. Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005, 49(2):627-31. 10.1128/AAC.49.2.627-631.2005, 547312, 15673743.
27. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004, 169(3):421-6. 10.1164/rccm.200310-1380OC, 14578218.
28. Gosling R, Gillespie S. Moxifloxacin treatment of tuberculosis. Antimicrob Agents Chemother 2004, 48(9):3642. author reply 3642-3, 10.1128/AAC.48.9.3642-3643.2004, 514750, 15328148.
29. Tortoli E, Dionisio D, Fabbri C. Evaluation of moxifloxacin activity in vitro against Mycobacterium tuberculosis, including resistant and multidrug-resistant strains. J Chemother 2004, 16(4):334-6.
30. Yew WW, Chan CK, Leung CC, Chau CH, Tam CM, Wong PC, Lee J. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003, 124(4):1476-81. 10.1378/chest.124.4.1476, 14555582.
31. Fattorini L, Tan D, Iona E, Mattei M, Giannoni F, Brunori L, Recchia S, Orefici G. Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice. Antimicrob Agents Chemother 2003, 47(1):360-2. 10.1128/AAC.47.1.360-362.2003, 149032, 12499213.
32. Sato K, Tomioka H, Sano C, Shimizu T, Sano K, Ogasawara K, Cai S, Kamei T. Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines. J Antimicrob Chemother 2003, 52(2):199-203. 10.1093/jac/dkg343, 12865388.
33. Cynamon MH, Sklaney M. Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrob Agents Chemother 2003, 47(8):2442-4. 10.1128/AAC.47.8.2442-2444.2003, 166105, 12878502.
34. Alvirez-Freites EJ, Carter JL, Cynamon MH. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002, 46(4):1022-5. 10.1128/AAC.46.4.1022-1025.2002, 127120, 11897584.
35. Rodriguez JC, Ruiz M, López M, Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2002, 20(6):464-7. 10.1016/S0924-8579(02)00239-X, 12458143.
36. Sirgel FA, Botha FJ, Parkin DP, Van de Wal BW, Schall R, Donald PR, Mitchison DA. The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1997, 156(3 Pt 1):901-5.
37. Kennedy N, Fox R, Uiso L, Ngowi FI, Gillespie SH. Safety profile of ciprofloxacin during long-term therapy for pulmonary tuberculosis. J Antimicrob Chemother 1993, 32(6):897-902. 10.1093/jac/32.6.897, 8144431.
38. Rodriguez JC, et al. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents 2001, 17(3):229-31. 10.1016/S0924-8579(00)00337-X, 11282270.
39. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006, 58(6):1299-302. 10.1093/jac/dkl399, 17032686.
40. Agresti A. Categorical Data Analysis. 2002, Wiley, 2.
41. Wolbers M, Heemskerk D, Chau TTH, Yen NTB, Caws M, Farrar J, Day J. Sample Size Requirements for Separating out the Effects of Combination Treatments: Randomised Controlled Trials of Combination Therapy vs. Standard Treatment Compared to Factorial Designs for Patients with Tuberculous Meningitis. Trials 2011, 12:26.